Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 256

1.

International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design.

ISCHEMIA Trial Research Group, Maron DJ, Hochman JS, O'Brien SM, Reynolds HR, Boden WE, Stone GW, Bangalore S, Spertus JA, Mark DB, Alexander KP, Shaw L, Berger JS, Ferguson TB Jr, Williams DO, Harrington RA, Rosenberg Y.

Am Heart J. 2018 Apr 21;201:124-135. doi: 10.1016/j.ahj.2018.04.011. [Epub ahead of print]

PMID:
29778671
2.

Interventional Cardiology: The In and the Out.

Carreras ET, Williams DO.

Circ Cardiovasc Interv. 2018 Apr;11(4):e006709. doi: 10.1161/CIRCINTERVENTIONS.118.006709. No abstract available.

PMID:
29654120
3.

Percutaneous Revascularization of Chronic Total Coronary Occlusion: For Whom?

Ng AK, Shah PB, Williams DO.

Circ Cardiovasc Interv. 2017 Jun;10(6). pii: e005512. doi: 10.1161/CIRCINTERVENTIONS.117.005512. No abstract available.

PMID:
28615235
4.

Coronary Brachytherapy 2016.

Williams DO, Sobieszczyk P.

JACC Cardiovasc Interv. 2016 Jun 27;9(12):1266-8. doi: 10.1016/j.jcin.2016.04.033. Epub 2016 Jun 20. No abstract available.

5.

Interventional Cardiology: Current Status and Future Directions in Coronary Disease and Valvular Heart Disease.

Faxon DP, Williams DO.

Circulation. 2016 Jun 21;133(25):2697-711. doi: 10.1161/CIRCULATIONAHA.116.023551. Review. No abstract available.

6.

Prevention of Contrast-Induced Renal Failure for the Interventional Cardiologist.

Chau CH, Williams DO.

Circ Cardiovasc Interv. 2016 Jun;9(6). pii: e004122. doi: 10.1161/CIRCINTERVENTIONS.116.004122. No abstract available.

7.

Medical Therapy With Versus Without Revascularization in Stable Patients With Moderate and Severe Ischemia: The Case for Community Equipoise.

Stone GW, Hochman JS, Williams DO, Boden WE, Ferguson TB Jr, Harrington RA, Maron DJ.

J Am Coll Cardiol. 2016 Jan 5;67(1):81-99. doi: 10.1016/j.jacc.2015.09.056. Epub 2015 Nov 23. Review.

8.

Transcatheter aortic valve replacement and stroke.

Wimmer NJ, Williams DO.

Circ Cardiovasc Interv. 2015 Jun;8(6). pii: e002801. doi: 10.1161/CIRCINTERVENTIONS.115.002801. No abstract available.

9.

Comparison of long-term safety and efficacy outcomes after drug-eluting and bare-metal stent use across racial groups: Insights from NHLBI Dynamic Registry.

Olafiranye O, Vlachos H, Mulukutla SR, Marroquin OC, Selzer F, Kelsey SF, Williams DO, Strollo PJ, Reis SE, Lee JS, Smith AJ.

Int J Cardiol. 2015 Apr 1;184:79-85. doi: 10.1016/j.ijcard.2015.01.071. Epub 2015 Jan 27.

10.

Cardiac surgery with percutaneous interventional backup: a paradigm shift.

Williams DO.

Circ Cardiovasc Interv. 2014 Jun;7(3):275-7. doi: 10.1161/CIRCINTERVENTIONS.114.001631. No abstract available.

11.

Trends in major entry site complications from percutaneous coronary intervention (from the Dynamic Registry).

Young K, Earl T, Selzer F, Marroquin OC, Mulukutla SR, Cohen HA, Williams DO, Jacobs A, Kelsey SF, Abbott JD.

Am J Cardiol. 2014 Feb 15;113(4):626-30. doi: 10.1016/j.amjcard.2013.11.005. Epub 2013 Nov 23.

12.

Comparison of drug-eluting and bare metal stents in large coronary arteries: findings from the NHLBI dynamic registry.

Chan CY, Vlachos H, Selzer F, Mulukutla SR, Marroquin OC, Abbott DJ, Holper EM, Williams DO.

Catheter Cardiovasc Interv. 2014 Jul 1;84(1):24-9. doi: 10.1002/ccd.25339. Epub 2014 Jan 6.

PMID:
24323698
13.

Response to Dr Sandar et al.

Carson JL, Brooks MM, Abbott JD, Kelsey SF, Triulzi DJ, Menegus MA, Marroquin OC, Rao SV, Smitherman T, Vagaonescu T, Wimmer NJ, Williams DO.

Am Heart J. 2013 Oct;166(4):e27-8. doi: 10.1016/j.ahj.2013.07.022. Epub 2013 Aug 29. No abstract available.

PMID:
24093866
14.

Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease.

Carson JL, Brooks MM, Abbott JD, Chaitman B, Kelsey SF, Triulzi DJ, Srinivas V, Menegus MA, Marroquin OC, Rao SV, Noveck H, Passano E, Hardison RM, Smitherman T, Vagaonescu T, Wimmer NJ, Williams DO.

Am Heart J. 2013 Jun;165(6):964-971.e1. doi: 10.1016/j.ahj.2013.03.001. Epub 2013 Apr 8.

15.

A randomized, controlled, multicenter trial to evaluate the safety and efficacy of Zotarolimus- vs. Paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries: five-year results from the ZOMAXX I trial.

Chevalier B, Dimario C, Neumann FJ, Cutlip DE, Williams DO, Ormiston J, Grube E, Whitbourn R, Coe J, Schwartz LB; ZOMAXX I Investigators.

Catheter Cardiovasc Interv. 2013 Dec 1;82(7):1039-47. doi: 10.1002/ccd.24958. Epub 2013 Jul 25.

PMID:
23592567
16.

Coronary revascularization for myocardial ischemia.

Chan P, Williams DO.

Circ Cardiovasc Interv. 2013 Apr;6(2):123-4. doi: 10.1161/CIRCINTERVENTIONS.113.000360. No abstract available.

17.

Benefit of long-term dual anti-platelet therapy in patients treated with drug-eluting stents: from the NHLBI dynamic registry.

Mulukutla SR, Marroquin OC, Vlachos HA, Selzer F, Toma C, Kip KE, Abbott JD, Holper E, Lee JS, Khandhar S, Kutcher M, Kelsey S, Smith C, Faxon D, Williams DO.

Am J Cardiol. 2013 Feb 15;111(4):486-92. doi: 10.1016/j.amjcard.2012.10.030. Epub 2012 Dec 1.

18.

Clinical presentation and predictors of target vessel revascularization after drug-eluting stent implantation.

Al Muradi H, Mehra A, Okolo J, Vlachos H, Selzer F, Marroquin OC, Skelding K, Holper EM, Williams DO, Abbott JD.

Cardiovasc Revasc Med. 2012 Nov-Dec;13(6):311-5. doi: 10.1016/j.carrev.2012.10.003.

19.

Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials.

Bangalore S, Kumar S, Fusaro M, Amoroso N, Kirtane AJ, Byrne RA, Williams DO, Slater J, Cutlip DE, Feit F.

BMJ. 2012 Aug 10;345:e5170. doi: 10.1136/bmj.e5170.

20.

Incidence and predictors of 30-day hospital readmission rate following percutaneous coronary intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry).

Ricciardi MJ, Selzer F, Marroquin OC, Holper EM, Venkitachalam L, Williams DO, Kelsey SF, Laskey WK.

Am J Cardiol. 2012 Nov 15;110(10):1389-96. doi: 10.1016/j.amjcard.2012.07.002. Epub 2012 Jul 30.

21.

Comparison of bare-metal stents and drug-eluting stents in coronary ostial lesions (from the National Heart, Lung, and Blood Institute Dynamic Registry).

Vasaiwala S, Vlachos H, Selzer F, Marroquin O, Mulukutla S, Abbott JD, Williams DO.

Am J Cardiol. 2012 Oct 15;110(8):1113-8. doi: 10.1016/j.amjcard.2012.05.051. Epub 2012 Jul 3.

22.

The changing face of interventional cardiology.

Faxon DP, Williams DO.

Circ Cardiovasc Interv. 2012 Jun;5(3):325-7. doi: 10.1161/CIRCINTERVENTIONS.112.971671. No abstract available.

23.

Revascularization for left main and multivessel coronary artery disease in the drug-eluting stent era: integration of recent drug-eluting stent trials.

Vasaiwala S, Williams DO.

Curr Cardiol Rep. 2012 Aug;14(4):468-76. doi: 10.1007/s11886-012-0274-x. Review.

PMID:
22638907
24.

Medical device regulatory landscape: the imperative of finding balance.

Kaplan AV, Williams DO.

Circ Cardiovasc Interv. 2012 Feb 1;5(1):2-5. doi: 10.1161/CIRCINTERVENTIONS.112.968560. No abstract available.

25.

Outcomes of drug-eluting stents for protected left main coronary artery disease (from the Multicenter, United States DEScover registry).

Leitner J, Vlachos HA, Selzer F, Jamal SM, Kip KE, Williams DO, Abbott JD.

Am J Cardiol. 2012 Feb 15;109(4):466-70. doi: 10.1016/j.amjcard.2011.09.038. Epub 2011 Nov 24.

PMID:
22118825
26.

Comparison of three age groups regarding safety and efficacy of drug-eluting stents (from the National Heart, Lung, and Blood Institute Dynamic Registry).

Bainey KR, Selzer F, Cohen HA, Marroquin OC, Holper EM, Graham MM, Williams DO, Faxon DP.

Am J Cardiol. 2012 Jan 15;109(2):195-201. doi: 10.1016/j.amjcard.2011.08.028. Epub 2011 Oct 14.

27.

Comparison of bare-metal and drug-eluting stents in patients with chronic kidney disease (from the NHLBI Dynamic Registry).

Green SM, Selzer F, Mulukutla SR, Tadajweski EJ, Green JA, Wilensky RL, Laskey WK, Cohen HA, Rao SV, Weisbord SD, Lee JS, Reis SE, Kip KE, Kelsey SF, Williams DO, Marroquin OC.

Am J Cardiol. 2011 Dec 1;108(11):1658-64. doi: 10.1016/j.amjcard.2011.07.029. Epub 2011 Sep 3.

28.

A randomized, controlled, multi-center trial comparing the safety and efficacy of zotarolimus-eluting and paclitaxel-eluting stents in de novo lesions in coronary arteries: final results of the ZoMaxx II trial.

Gray WA, Yeung AC, Cutlip DE, Popma JJ, Fitzgerald PJ, Williams DO, Heuer H, O'Shaughnessy CD, Overlie PA, Mann JT, Cannon LA, Hermiller JB, Henry TD, Whitbourn R, Stuckey TD, Midei MG, Coe J, Schwartz LB.

Int J Cardiol. 2012 May 17;157(1):96-101. doi: 10.1016/j.ijcard.2011.05.061. Epub 2011 Jun 11.

PMID:
21658783
29.

Direct stenting compared to balloon predilation in drug-eluting stents: one-year outcomes from the DEScover Registry.

Abbott JD, Earl T, Vlachos HE, Selzer F, Vaidya KA, Romero A, Kip KE, Williams DO.

Catheter Cardiovasc Interv. 2012 Jan 1;79(1):84-9. doi: 10.1002/ccd.22914. Epub 2011 Mar 16.

PMID:
21413133
30.

Stent thrombosis.

Holmes DR Jr, Kereiakes DJ, Garg S, Serruys PW, Dehmer GJ, Ellis SG, Williams DO, Kimura T, Moliterno DJ.

J Am Coll Cardiol. 2010 Oct 19;56(17):1357-65. doi: 10.1016/j.jacc.2010.07.016. Review.

31.

Association of an INSIG2 obesity allele with cardiovascular phenotypes is gender and age dependent.

Skelding KA, Gerhard GS, Vlachos H, Selzer F, Kelsey SF, Chu X, Erdman R, Williams DO, Kip KE.

BMC Cardiovasc Disord. 2010 Sep 29;10:46. doi: 10.1186/1471-2261-10-46.

32.

Comparison of drug-eluting and bare metal stents for saphenous vein graft lesions (from the National Heart, Lung, and Blood Institute Dynamic Registry).

Baldwin DE, Abbott JD, Trost JC, Vlachos HA, Selzer F, Glaser R, Wilensky RL, Slater JN, Doucet S, Naidu SS, Aronow HD, Williams DO.

Am J Cardiol. 2010 Oct 1;106(7):946-51. doi: 10.1016/j.amjcard.2010.05.025. Epub 2010 Aug 11.

33.

Is optimal medical therapy "optimal therapy" for multivessel coronary artery disease? Optimal management of multivessel coronary artery disease.

Williams DO, Vasaiwala SC, Boden WE.

Circulation. 2010 Sep 7;122(10):943-5. doi: 10.1161/CIRCULATIONAHA.110.969980. Epub 2010 Aug 23. No abstract available. Erratum in: Circulation. 2010 Nov 16;122(20):e524.

34.

A technical and cognitive skills evaluation of performance in interventional cardiology procedures using medical simulation.

Lipner RS, Messenger JC, Kangilaski R, Baim DS, Holmes DR Jr, Williams DO, King SB 3rd.

Simul Healthc. 2010 Apr;5(2):65-74. doi: 10.1097/SIH.0b013e3181c75f8e.

PMID:
20661006
35.

Percutaneous coronary intervention of moderate to severe calcified coronary lesions: insights from the National Heart, Lung, and Blood Institute Dynamic Registry.

Bangalore S, Vlachos HA, Selzer F, Wilensky RL, Kip KE, Williams DO, Faxon DP.

Catheter Cardiovasc Interv. 2011 Jan 1;77(1):22-8. doi: 10.1002/ccd.22613.

36.

Paclitaxel-eluting versus sirolimus-eluting stents in diabetes mellitus: a report from the National Heart, Lung, and Blood Institute Dynamic Registry.

Wolf WM, Vlachos HA, Marroquin OC, Lee JS, Smith C, Anderson WD, Schindler JT, Holper EM, Abbott JD, Williams DO, Laskey WK, Kip KE, Kelsey SF, Mulukutla SR.

Circ Cardiovasc Interv. 2010 Feb 1;3(1):42-9. doi: 10.1161/CIRCINTERVENTIONS.109.885996. Epub 2010 Jan 26.

37.

Temporal trends in patient-reported angina at 1 year after percutaneous coronary revascularization in the stent era: a report from the National Heart, Lung, and Blood Institute-sponsored 1997-2006 dynamic registry.

Venkitachalam L, Kip KE, Mulukutla SR, Selzer F, Laskey W, Slater J, Cohen HA, Wilensky RL, Williams DO, Marroquin OC, Sutton-Tyrrell K, Bunker CH, Kelsey SF; NHLBI-Sponsored Dynamic Registry Investigators.

Circ Cardiovasc Qual Outcomes. 2009 Nov;2(6):607-15. doi: 10.1161/CIRCOUTCOMES.109.869131. Epub 2009 Oct 13.

38.

Twenty-year evolution of percutaneous coronary intervention and its impact on clinical outcomes: a report from the National Heart, Lung, and Blood Institute-sponsored, multicenter 1985-1986 PTCA and 1997-2006 Dynamic Registries.

Venkitachalam L, Kip KE, Selzer F, Wilensky RL, Slater J, Mulukutla SR, Marroquin OC, Block PC, Williams DO, Kelsey SF; Investigators of NHLBI-Sponsored 1985-1986 PTCA and 1997-2006 Dynamic Registries.

Circ Cardiovasc Interv. 2009 Feb;2(1):6-13. doi: 10.1161/CIRCINTERVENTIONS.108.825323. Epub 2008 Dec 15.

39.

Poor 1-year outcomes after percutaneous coronary interventions in systemic lupus erythematosus: report from the National Heart, Lung, and Blood Institute Dynamic Registry.

Maksimowicz-McKinnon K, Selzer F, Manzi S, Kip KE, Mulukutla SR, Marroquin OC, Smitherman TC, Kuller LH, Williams DO, Wasko MC.

Circ Cardiovasc Interv. 2008 Dec;1(3):201-8. doi: 10.1161/CIRCINTERVENTIONS.108.788745.

40.

2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC, Casey DE Jr, Green LA, Hochman JS, Jacobs AK, Krumholz HM, Morrison DA, Ornato JP, Pearle DL, Peterson ED, Sloan MA, Whitlow PL, Williams DO.

J Am Coll Cardiol. 2009 Dec 1;54(23):2205-41. doi: 10.1016/j.jacc.2009.10.015. Review. No abstract available. Erratum in: J Am Coll Cardiol. 2009 Dec 15;54(25):2464. J Am Coll Cardiol. 2010 Feb 9;55(6):612. Dosage error in article text.

41.

2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC, Casey DE Jr, Green LA, Jacobs AK, Hochman JS, Krumholz HM, Morrison DA, Ornato JP, Pearle DL, Peterson ED, Sloan MA, Whitlow PL, Williams DO; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines.

Catheter Cardiovasc Interv. 2009 Dec 1;74(7):E25-68. doi: 10.1002/ccd.22351. Review. No abstract available. Erratum in: Catheter Cardiovasc Interv. 2010 Jun 1;75(7):1143. Dosage error in article text.

PMID:
19924773
42.

2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC, Casey DE Jr, Green LA, Hochman JS, Jacobs AK, Krumholz HM, Morrison DA, Ornato JP, Pearle DL, Peterson ED, Sloan MA, Whitlow PL, Williams DO; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Circulation. 2009 Dec 1;120(22):2271-306. doi: 10.1161/CIRCULATIONAHA.109.192663. Epub 2009 Nov 18. No abstract available. Erratum in: Circulation. 2010 Mar 30;121(12):e257. Dosage error in article text.

43.

Diabetes mellitus does not unsweeten left main intervention.

Williams DO, Abbott JD.

JACC Cardiovasc Interv. 2009 Oct;2(10):964-6. doi: 10.1016/j.jcin.2009.08.014. No abstract available.

44.

Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study.

Block PC, Burstein S, Casale PN, Kramer PH, Teirstein P, Williams DO, Reisman M.

JACC Cardiovasc Interv. 2009 Jul;2(7):594-600. doi: 10.1016/j.jcin.2009.05.005.

45.

A randomized, controlled, multicenter trial to evaluate the safety and efficacy of zotarolimus- versus paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries The ZoMaxx I trial.

Chevalier B, Di Mario C, Neumann FJ, Ribichini F, Urban P, Popma JJ, Fitzgerald PJ, Cutlip DE, Williams DO, Ormiston J, Grube E, Whitbourn R, Schwartz LB; ZoMaxx I Investigators.

JACC Cardiovasc Interv. 2008 Oct;1(5):524-32. doi: 10.1016/j.jcin.2008.08.010.

46.

Beneficial effects of statins after percutaneous coronary intervention.

Zhang ZJ, Marroquin OC, Weissfeld JL, Stone RA, Mulukutla SR, Williams DO, Selzer F, Kip KE.

Eur J Cardiovasc Prev Rehabil. 2009 Aug;16(4):445-50. doi: 10.1097/HJR.0b013e32832a4e3b.

47.

Impact of drug-eluting stents among insulin-treated diabetic patients: a report from the National Heart, Lung, and Blood Institute Dynamic Registry.

Mulukutla SR, Vlachos HA, Marroquin OC, Selzer F, Holper EM, Abbott JD, Laskey WK, Williams DO, Smith C, Anderson WD, Lee JS, Srinivas V, Kelsey SF, Kip KE.

JACC Cardiovasc Interv. 2008 Apr;1(2):139-47. doi: 10.1016/j.jcin.2008.02.005.

48.

What to do with patients receiving long-term clopidogrel: reload or relax?

Williams DO, Abbott JD.

Circulation. 2008 Sep 16;118(12):1219-22. doi: 10.1161/CIRCULATIONAHA.108.804229. No abstract available.

49.

Catheter-based treatment of coronary artery disease: past, present, and future.

Holmes DR Jr, Williams DO.

Circ Cardiovasc Interv. 2008 Aug;1(1):60-73. doi: 10.1161/CIRCINTERVENTIONS.108.783134. Review.

50.

Postmarket evaluation of breakthrough technologies.

Rao SV, Califf RM, Kramer JM, Peterson ED, Gross TP, Pepine CJ, Williams DO, Donohoe D, Waksman R, Mehran R, Krucoff MW.

Am Heart J. 2008 Aug;156(2):201-8. doi: 10.1016/j.ahj.2008.01.036.

PMID:
18657647

Supplemental Content

Loading ...
Support Center